JP2017529851A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017529851A5 JP2017529851A5 JP2017516350A JP2017516350A JP2017529851A5 JP 2017529851 A5 JP2017529851 A5 JP 2017529851A5 JP 2017516350 A JP2017516350 A JP 2017516350A JP 2017516350 A JP2017516350 A JP 2017516350A JP 2017529851 A5 JP2017529851 A5 JP 2017529851A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cells
- car
- cell
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 22
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 19
- 210000004027 cell Anatomy 0.000 claims 11
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 9
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 9
- 102000010956 Glypican Human genes 0.000 claims 8
- 108050001154 Glypican Proteins 0.000 claims 8
- 108050007237 Glypican-3 Proteins 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- 210000002865 immune cell Anatomy 0.000 claims 7
- -1 CD8α Proteins 0.000 claims 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims 5
- 230000011664 signaling Effects 0.000 claims 5
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 4
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000000139 costimulatory effect Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 208000006332 Choriocarcinoma Diseases 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 208000008938 Rhabdoid tumor Diseases 0.000 claims 1
- 206010073334 Rhabdoid tumour Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000003874 Simpson-Golabi-Behmel syndrome Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 208000012018 Yolk sac tumor Diseases 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 210000004544 dc2 Anatomy 0.000 claims 1
- 208000001991 endodermal sinus tumor Diseases 0.000 claims 1
- 230000001605 fetal effect Effects 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 210000000581 natural killer T-cell Anatomy 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462055979P | 2014-09-26 | 2014-09-26 | |
| US62/055,979 | 2014-09-26 | ||
| PCT/US2015/052227 WO2016049459A1 (en) | 2014-09-26 | 2015-09-25 | Glypican-3 specific chimeric antigen receptors for adoptive immunotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017529851A JP2017529851A (ja) | 2017-10-12 |
| JP2017529851A5 true JP2017529851A5 (OSRAM) | 2018-11-08 |
Family
ID=55582053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017516350A Pending JP2017529851A (ja) | 2014-09-26 | 2015-09-25 | 養子免疫療法のためのグリピカン−３特異的キメラ抗原レセプター |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20170281683A1 (OSRAM) |
| EP (2) | EP3858991A1 (OSRAM) |
| JP (1) | JP2017529851A (OSRAM) |
| DE (1) | DE20196219T1 (OSRAM) |
| ES (2) | ES2851123T1 (OSRAM) |
| WO (1) | WO2016049459A1 (OSRAM) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7080819B2 (ja) | 2016-02-25 | 2022-06-06 | セル メディカ スイッツァランド アーゲー | Ｐｄ－ｌ１に対する結合メンバー |
| CN121102467A (zh) * | 2016-04-22 | 2025-12-12 | 克莱格医学有限公司 | 用于细胞免疫疗法的组合物和方法 |
| AU2017301826A1 (en) | 2016-07-26 | 2019-03-14 | Tessa Therapeutics Ltd. | Chimeric antigen receptor |
| AU2017366739B2 (en) | 2016-12-02 | 2023-11-23 | Angeles Therapeutics, Inc. | Synthetic immune receptors and methods of use thereof |
| JP2018093823A (ja) * | 2016-12-15 | 2018-06-21 | Ｈｅａｒｔｓｅｅｄ株式会社 | 未分化幹細胞除去剤及び未分化幹細胞除去方法 |
| KR102564097B1 (ko) * | 2017-01-10 | 2023-08-04 | 고쿠리츠다이가쿠호우진 야마구치 다이가쿠 | 항 gpc3 항체 |
| IL270138B2 (en) * | 2017-04-26 | 2025-08-01 | Eureka Therapeutics Inc | Structures that specifically recognize glypican 3 and their uses |
| EP3441461A1 (en) * | 2017-08-11 | 2019-02-13 | Baylor College of Medicine | Cd1d-restricted nkt cells as a platform for off-the-shelf cancer immunotherapy |
| EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| TWI809130B (zh) | 2018-06-22 | 2023-07-21 | 美商凱特製藥公司 | 嵌合跨膜蛋白及其用途 |
| US20210261646A1 (en) * | 2018-07-03 | 2021-08-26 | Sotio, LLC | Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof |
| WO2020017479A1 (ja) * | 2018-07-17 | 2020-01-23 | ノイルイミューン・バイオテック株式会社 | 抗ｇｐｃ３一本鎖抗体を含むｃａｒ |
| IL280322B2 (en) | 2018-08-14 | 2025-06-01 | Sotio Llc | Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating krebs cycle and therapeutic uses thereof |
| AU2019354395A1 (en) | 2018-10-01 | 2021-05-06 | Adicet Therapeutics, Inc. | Compositions and methods regarding engineered and non-engineered γδ -T cells for treatment of solid tumors |
| US20210386788A1 (en) | 2018-10-24 | 2021-12-16 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
| CN113260368B (zh) * | 2018-11-07 | 2023-08-29 | 舒迪安生物技术公司 | 抗gpc3嵌合抗原受体(car)与反式共刺激分子的组合及其治疗用途 |
| US12227551B2 (en) | 2018-12-11 | 2025-02-18 | Obsidian Therapeutics, Inc. | Membrane bound IL12 compositions and methods for tunable regulation |
| US20220016171A1 (en) * | 2018-12-18 | 2022-01-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Mucosal-associated invariant t (mait) cells expressing chimeric antigen receptors |
| SG11202109172TA (en) | 2019-03-08 | 2021-09-29 | Obsidian Therapeutics Inc | Human carbonic anhydrase 2 compositions and methods for tunable regulation |
| US20220195397A1 (en) * | 2019-04-04 | 2022-06-23 | Shanghai Pharmaceuticals Holding Co., Ltd. | Immune cell containing tumor antigen recognition receptor and application thereof |
| BR112021025022A2 (pt) | 2019-06-12 | 2022-02-22 | Obsidian Therapeutics Inc | Composições de ca2 e métodos para regulação ajustáveis |
| EP3983537A1 (en) | 2019-06-12 | 2022-04-20 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| JP2022536975A (ja) | 2019-06-21 | 2022-08-22 | カイト ファーマ インコーポレイテッド | ＴＧＦ－β受容体及び使用方法 |
| WO2021046451A1 (en) | 2019-09-06 | 2021-03-11 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| EP4121516A4 (en) * | 2020-03-18 | 2024-06-05 | Eutilex Co., Ltd. | Gpc3 car-t cell compositions and methods of making and using the same |
| EP4121517A4 (en) * | 2020-03-18 | 2024-08-07 | Eutilex Co., Ltd. | IL-18-SECRETING GPC3 CAR-T CELLS AND METHODS OF MAKING AND USING THE SAME |
| US20230310606A1 (en) | 2020-07-17 | 2023-10-05 | Simurx, Inc. | Chimeric myd88 receptors for redirecting immunosuppressive signaling and related compositions and methods |
| CN112225822B (zh) * | 2020-12-14 | 2021-03-23 | 北京基因启明生物科技有限公司 | 高扩增、存续能力和杀瘤作用的CAR-iNKT及应用 |
| US11883432B2 (en) | 2020-12-18 | 2024-01-30 | Century Therapeutics, Inc. | Chimeric antigen receptor system with adaptable receptor specificity |
| WO2022214089A1 (zh) | 2021-04-08 | 2022-10-13 | 克莱格医学有限公司 | 细胞免疫治疗的应用 |
| JP2024545363A (ja) | 2021-11-16 | 2024-12-05 | ソティオ・バイオテック・インコーポレイテッド | 粘液型／円形細胞型脂肪肉腫患者の治療 |
| CN117230174A (zh) * | 2023-04-03 | 2023-12-15 | 上海交通大学医学院附属瑞金医院 | Gpc3在诊断特发性肺纤维化中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| AU2006277295B2 (en) * | 2005-08-09 | 2011-08-11 | Oncotherapy Science, Inc. | Glypican-3 (GPC3)-derived tumor rejection antigenic peptides useful for HLA-A2-positive patients and pharmaceutical comprising the same |
| ES2666550T3 (es) * | 2011-04-19 | 2018-05-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anticuerpos monoclonales humanos específicos para glipicano 3 y uso de los mismos |
| US20140255363A1 (en) * | 2011-09-16 | 2014-09-11 | Baylor College Of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| US20140322216A1 (en) | 2011-11-08 | 2014-10-30 | The Trustees Of The University Of Pennsylvania | Glypican-3-specific antibody and uses thereof |
| JP2016512199A (ja) * | 2013-03-05 | 2016-04-25 | ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ | 腫瘍溶解性ウイルス |
| CN104140974B (zh) * | 2013-05-08 | 2017-09-29 | 科济生物医药（上海）有限公司 | 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞 |
| CN106397593B (zh) * | 2015-08-03 | 2019-09-10 | 科济生物医药（上海）有限公司 | 抗磷脂酰肌醇蛋白多糖-3的抗体及其应用 |
-
2015
- 2015-09-25 WO PCT/US2015/052227 patent/WO2016049459A1/en not_active Ceased
- 2015-09-25 US US15/513,900 patent/US20170281683A1/en not_active Abandoned
- 2015-09-25 DE DE20196219.8T patent/DE20196219T1/de active Pending
- 2015-09-25 ES ES20196219T patent/ES2851123T1/es active Pending
- 2015-09-25 EP EP20196219.8A patent/EP3858991A1/en active Pending
- 2015-09-25 JP JP2017516350A patent/JP2017529851A/ja active Pending
- 2015-09-25 ES ES15845117T patent/ES2844700T3/es active Active
- 2015-09-25 EP EP15845117.9A patent/EP3198010B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017529851A5 (OSRAM) | ||
| Mizukoshi et al. | Immune cell therapy for hepatocellular carcinoma | |
| JP2021506243A5 (OSRAM) | ||
| IL292650A (en) | Chimeric antigen receptor T cells target il13ra2 | |
| RU2018113510A (ru) | Химерные рецепторы антигена, нацеленные на psca | |
| RU2018107802A (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
| JP2019527557A5 (OSRAM) | ||
| JP2016534717A5 (OSRAM) | ||
| JP2019528769A5 (OSRAM) | ||
| HRP20211978T1 (hr) | Kimerični antigenski receptori koji ciljaju receptor spojen na g-protein i njihove uporabe | |
| JP2017513478A5 (OSRAM) | ||
| JP2016502512A5 (OSRAM) | ||
| RU2017121826A (ru) | Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1 | |
| JP2019500894A5 (OSRAM) | ||
| JP2017522862A5 (OSRAM) | ||
| JP2018506981A5 (OSRAM) | ||
| MY186846A (en) | Method and compositions for cellular immunotherapy | |
| JP2017518037A5 (OSRAM) | ||
| JP2016508728A5 (OSRAM) | ||
| RU2018105963A (ru) | Антитело против глипикана-3 и его применение | |
| WO2017011804A8 (en) | Engineered cells for adoptive cell therapy | |
| EP4424376A3 (en) | Chimeric antigen receptors based on single-domain antibodies and methods of use thereof | |
| EP4537839A3 (en) | Method and compositions for cellular immunotherapy | |
| JP2017538401A5 (OSRAM) | ||
| JP2015509717A5 (OSRAM) |